metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144 A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial risk, with a sixfold increased risk of breast cancer death. This prospective multicenter cohort study was set up to validate the index.
introduction
Over the last years, much effort has been put into identifying low-risk node-negative breast cancer patients, for whom extensive adjuvant therapy can be avoided. Apart from the established prognostic factors age, tumour size, oestrogen and progesterone receptor status (ER and PR), human epidermal growth factor receptor 2 (HER2), histological grade, and tumour size, proliferation assessed by Ki67 is now being recommended for use when deciding risk and adjuvant medical treatment, specifically to distinguish between the 'luminal A-' and 'luminal B-like' subtypes [1] . Proliferation genes are the main common denominator in the majority of genetic profiles [2] , which also to some extent are recommended for clinical use [3] . There are however no published prospective trials for Ki67 or genetic profiles. Only the proliferation factors mitotic activity index (MAI) [4] , thymidine labelling index (TLI) [5, 6] , and flow cytometric assessment of fraction of cells in S-phase (SPF) [7, 8] , have been validated in prospective trials, and thus reached evidence level 1, generally considered a prerequisite for a factor to be recommended for widespread clinical use [9, 10] . The uses of TLI and SPF have however been limited due to the need of fresh or frozen tumour tissue [11] . To our knowledge, the only other prognostic factors that have reached evidence level 1 are uPA/PAI-1 [12] and bone marrow micrometastases [13] . In an earlier retrospective study from our group on nodenegative breast cancer patients, a prognostic index consisting of PR-status, tumour size, and a proliferation factor, SPF, identified one-third of the patients as high risk, with a sixfold increased risk of breast cancer death [14] . Low-risk patients were found to have a survival equalling that of an age-sex-, and calendar-time-matched Swedish cohort. High risk was defined as two or more of the following: (i) size >20 mm, (ii) PRnegativity, and (iii) high SPF. The present prospective study, entitled 'The Node Negative Breast Cancer Trial' (NNBC), was therefore initiated by the Swedish Breast Cancer Group, SweBCG, to validate the prognostic value of the index in a multicenter cohort including pT1-T2 node-negative patients under the age of 60. The prognostic value of the index and its three components were validated with the primary end point breast cancer-specific survival (BCSS), and the secondary end point recurrence-free survival (RFS).
patients
Patients were from 1991 to 1995 recruited from 41 hospitals in three medical care regions in Sweden: region 1 (coordinated by Umeå University Hospital), region 2, (coordinated by the University Hospitals of Uppsala and Örebro), and region 3 (coordinated by Lund University Hospital). According to the study protocol, inclusion criteria were (i) tumour size 10-50 mm, (ii) node-negativity, (iii) age <60 years, (iv) radical surgery, (v) ≥5 lymph nodes removed. Exclusion criteria were bilateral breast cancer, pregnancy, and previous malignancy (excluding basal cell carcinoma and cervical dysplasia). From all patients, fresh frozen tissue from surgery was sent to four laboratories for prospective analyses of ER, PR, SPF, and/or histological grading according to the regional treatment programmes. A total of 576 patients were included in the study (region 1: n = 122, region 2: n = 169, region 3: n = 285). In a second part of the study, patients who were classified as high risk according to the index were offered randomization between nine cycles of cyclophosphamide, methotrexate, and fluorouracil versus no chemotherapy. Only 37 patients were randomized. As the numbers randomized were limited, the present publication focuses on the results from the whole cohort. A flowchart of the NNBC trial is presented as Figure 1 .
Primary surgical treatment, postoperative radiation, and adjuvant systemic treatment given according to the regional treatment plans, as well as patient-and tumour characteristics are presented in Table 1 . For regions 1 and 3, all patients underwent annual examinations at the departments of surgery and/or oncology. For region 2, all patients had initial annual examinations, and were then either included in the mammography screening programme, or continued annual examinations. All hospital medical records were assessed. For the primary end point BCSS, data from the National Causes of Death Register was obtained in August 2011. The median follow-up for the primary end point BCSS was 17.8 (range 16.5-20.3) years for the 397 patients alive and at risk at last follow-up. Follow-up was censored for all end points when patients were diagnosed with either a contralateral breast cancer (n = 16) or another malignancy (n = 20), Table 2 . Assumptions of proportional hazards, fundamental for Cox regression analysis, were violated with long follow-up. Hence, analyses were done for the time intervals 0-5, 0-10, and 0-15 as well as 0-5, 5-10, and 10-15 years after diagnosis. High risk was defined as having two or more of the following risk factors: (i) tumour size >20 mm, (ii) PR-negativity, or in the case of no PR-status available, ER-negativity, and (iii) high SPF, or in the case of no SPF available, Bloom-Richardson histological grade 3. The study was approved by the regional ethics committees.
methods analyses of ER and PR
Fresh tumour tissue was obtained perioperatively, and sent on dry ice to the four laboratories at the University hospitals in Lund, Uppsala, Linköping, or Umeå. ER and PR were measured routinely every week by enzyme immunoassay (EIA) on cytosol samples according to kit instructions and by routine procedures [15, 16] . PR-status was available for 573 of the patients. For the remaining three patients, ER-status was used for risk grouping.
flow cytometric analyses of cells in SPF Flow cytometric DNA analyses were carried out routinely on fresh frozen tumour tissue, after staining with propidium iodide at all four laboratories [16, 17] . According to the study protocol, high SPF for non-diploid tumours corresponded to values above the upper third, and for diploid tumours to values above the median [18, 19] , the same cut-off definitions as were used in the previous retrospective study [14] . SPF was available for 499 patients.
histological grading
In regions 1 and 2, histological grading according to Bloom-Richardson [20] was also routinely carried out. 232 patients had analyses of histological grading available. Of these, only data from the 77 patients with no SPF measurements available were used for risk grouping.
statistics
According to the study protocol, BCSS was the primary end point, and RFS, defined as the absence of local, regional, and/or distant recurrence, was the secondary end point. Also distant RFS (DRFS), overall survival (OS), and risk according to number of risk factors, were chosen as exploratory end points. Owing to competing risk, e.g. other causes of death, in analysis of BCSS, cumulative incidence functions were used for graphical presentation of time-to-event data [21] . The stratified log-rank test was used to compare survival in different strata and Cox proportional hazards model, stratified for region, for estimation of hazard ratios. Also competing risk regression by the method of Fine and Gray [22] was applied to BCSS data. As the estimates were very close to those from a standard Cox model, results are presented for the latter model only. Proportional hazards assumptions were checked both graphically and by Schoenfeld's test [23] . All factors were used as dichotomous covariates in the statistical analysis, with the exception of age, which was also analysed as a continuous variable. Cut-off values were chosen before statistical analyses. Associations between the factors were analysed using Pearson's χ 2 test. Expected Swedish mortality figures were downloaded from www.mortality.org, and sex-, age-, and calendar-time matched survival was estimated using Paul Dickman's routines for relative survival [www.pauldickman.com/rsmodel/stata]. All P-values correspond to two-sided tests and P < 0.05 was considered significant. The statistical calculations were carried out using Stata Version 12.1 (StataCorp 2012, College Station, TX). Detailed patient characteristics and data on recurrences and deaths for the 576 patients are found in Tables 1-2 and  supplementary Table S1 , available at Annals of Oncology online. The 5-, 10-, and 15-year cumulative breast cancer death incidences were 7.7%, 18%, and 20%, respectively. Corresponding 5-, 10-, and 15-year cumulative incidences for any relapse were 21%, 32%, and 40%, for distant relapse 14%, 23%, and 30%, and for death of all causes 8.2%, 20%, and 25%, respectively, supplementary Table S1, available at Annals of Oncology online. One hundred and eighty (31%) of the patients were identified as high risk according to the index, having two or more of the three risk factors, Table 1. breast cancer-specific survival univariate analyses. In univariate analysis, the index was prognostic for BCSS after 5 years (HR = 4.7, 95% CI 2.5-8.9, P < 0.001), 10 years (HR = 2.2, 95% CI 1.5-3.3, P < 0.001), as well as 15 years (HR = 1.7, 95% CI 1.2-2.5, P = 0.006), Table 3 . The 5-, 10-, and 15-year cumulative incidences (95% CI) were 3.8% (2.2-6.1), 14% (10) (11) (12) (13) (14) (15) (16) (17) , and 17% (14-21) for low-risk patients, compared with 16% (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , 26% (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) , and 26% (20-33) for high-risk patients, Figure 2A . Similar results were found when analysing only the 82% of patients who had not received any adjuvant medical treatment (data not shown). As an exploratory analysis of 5-year BCSS, PR was replaced with ER in the index, resulting in a similar HR of 4.9 (95% CI 2.6-9.2, P < 0.001).
When analysing the prognostic factors separately, the strongest factor for BCSS at 5 years was SPF (HR = 8.6, 95% CI 3.5-21), followed by PR, ER, grade, tumour size, and age, Table 3 . After 10 and 15 years, the strongest prognostic factor was grade (HR = 4.6, 95% CI 2.1-9.9, and HR = 5.1, 95% CI 2.5-10, respectively) followed by SPF, PR, ER, size, and age, Table 3 . It should however be noted that only 232 (40%) of all patients had data on grade, compared with 499 (87%) for SPF. Only 155 patients (26%) had data on both grade and SPF.
When analysing risk according to number of risk factors, a large group with very low risk and an excellent prognosis was identified (37% of all study patients, n = 212), who had none of the risk factors, in which only one patient died of breast cancer the first 5 years, Figure 2B . The 10-and 15-years cumulative incidences (95% CIs) for this group, of which only 3% had received adjuvant medical treatment, were 7.2% (4.2-11) and 11% (6.9-15), respectively. As this group had such a low incidence of breast cancer death, a comparison of all-cause 168 (29) a Years of follow-up for the end point BCSS for patients still alive and recurrence-free at the end of the study. Follow-up was censored for all end points at the time patients were diagnosed with either a contralateral breast cancer (n = 16) or another malignancy (n = 20).
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mortality was made with an age-, sex-, and calendar-timematched Swedish population [www.pauldickman.com/rsmodel/ stata]. As can be seen in Figure 2D , there is no difference in mortality the first 5 years. At 15 years, the difference in mortality between the groups is 10%. multivariate analyses. When adjusting for age and adjuvant medical treatment, the prognostic value of the index remained significant at 5 years (HR = 4.5, 95% CI 2.3-8.9, P < 0.001), 10 years (HR = 2.0, 95% CI 1.3-3.1, P = 0.002), and 15 years (HR = 1.6, 95% CI 1.0-2.4, P = 0.04), Table 4 .
recurrence-free survival univariate analyses. The index was prognostic for RFS at 5 years (HR = 1.9, 95% CI 1.3-2.8, P < 0.001), and 10 years (HR = 1.4, 95% CI 1.0-2.0, P = 0.03), but not at 15 years (HR = 1.3, 95% CI 0.97-1.8, P = 0.08), Figure 2C , supplementary Table S2 , available at Annals of Oncology online. The strongest single prognostic factor for recurrence the first 5 years was histological grade 3 (HR = 3.8, 95% CI 1.9-7.8, P < 0.001), followed by SPF, PR, ER, size, and age, supplementary Table S2 , available at Annals of Oncology online.
multivariate analyses. In multivariate analyses, the index remained prognostic at 5 years (HR = 1.8, 95% CI 1.2-2.8, P = 0.004), but not at 10 years (HR = 1.4, 95% CI 0.96-2.0, P = 0.08), or at 15 years (HR = 1.3, 95% CI 0.9-1.8, P = 0.17), supplementary Table S3 , available at Annals of Oncology online.
discussion
This prospective multicenter cohort validation study with longterm follow-up on node-negative breast cancer patients < 60 years, confirms that an index consisting of a proliferation marker, PR-status, and tumour size, reliably identifies one-third of the patients with a high risk of relapse. High-risk patients with two or more of the three risk factors [(i) size >20 mm, (ii) PR-negativity (in the absence of PR-status, ER-negativity) and (iii) high SPF (in the absence of SPF, Bloom-Richardson grade 3)] had an almost fivefold higher breast cancer mortality after 5 years. Interestingly, a large population with very low risk (37% of all study patients, n = 212) who had none of the risk factors and an excellent prognosis, was also identified. In this group of small, low-proliferating, PR-positive 'luminal A-like' tumours, only one patient died from breast cancer the first 5 years, and the 15-year cumulative incidence of breast cancer death was only 11%. It should also be noted that the majority, 82% of all patients in the study, and 97% of the patients with no risk factors, had not received any adjuvant medical treatment, and despite this, their risk of recurrence was very low. As all of the patients with no risk factors are PR-positive, the majority of them would today be offered adjuvant endocrine treatment, and there is reason to believe that this would even further improve their outcome. In the MINDACT trial [24] , the aim is to identify a low-risk population, with an estimated 5-year distant metastasis-free survival of 92% with adjuvant endocrine treatment only. This will include patients that are low risk according to Adjuvant Online and the 70-gene profile, but also a discordant population, with high risk according to Adjuvant Online, but low risk by the 70-gene profile. For these patients, an estimated 33% of the total patient population, the hypothesis is that they can safely be spared chemotherapy. However, use of the 70-gene profile is still very expensive. The present prospective study identifies a population of a similar size and with an equal distant metastases-free survival (92%, data not shown), by the use of conventional prognostic factors only. It should however be noted that in the pilot MINDACT trial, 62% of all patients so far are low risk [25] . original articles
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This study was set up as an independent prospective validation of results from a previous retrospective study on node-negative breast cancer [14] , and the results in the present study confirm these results. At the time when the present study was conducted, node-negative patients were generally not recommended any adjuvant medical treatment. As there are few confounders, and the follow-up is more than 15 years, the present patient population is ideal as a pure prognostic study population. The strongest single factor for recurrence in the index was proliferation. After 5 years, SPF was by far the strongest prognostic factor, with a HR of 8.6 at 5 years, but at 10 and 15 years the HRs were 2.3 and 1.9, respectively. Outcome for 576 women with node-negative breast cancer in the NNBC trial. (A) Cumulative incidence of breast cancer death by risk group. As seen, the main prognostic effect of the index is found the first 5 years. Between 5 and 10 years, there is no significant prognostic difference between the low-and high-risk group (P = 0.67), and between 10 and 15 years, the prognostic effect is inverted (P = 0.02), as all 14 deaths in that time period are found in the lowrisk group. (B) Cumulative incidence of breast cancer death by the number of risk factors (C) Cumulative incidence of any recurrence (D) Cumulative all-cause mortality for the patients with 0 risk factors, compared with the mortality of an age-, sex-, and time-calendar matched Swedish population. The difference between observed mortality is the excess mortality caused by breast cancer, which corresponds to the breast cancer mortality for the group with 0 risk factors in (B). Note the differences in scales on the y-axes. All models are stratified for region.
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Interestingly, the reverse was noted for Bloom-Richardson grade, which retained its prognostic value from 5 (HR = 3.1) to 10 (HR = 4.6), and even 15 years (HR = 5.1). These results should however be considered with caution, as evaluation of Bloom-Richardson grade was not a primary objective of the study, and only 40% of the patients had data on histological grade. So far, most known prognostic factors, including proliferation, only predict recurrences the first 5 years, and the prognostic value of a factor at 10 years is mostly due to its strong prognostic impact the first 5 years, but no extra value is added beyond 5 years. This was also true for the present study, where all 14 breast cancer deaths between 10 and 15 years occurred in the low-risk group, (Figure 2A) . The strong prognostic impact of proliferation found in the present study is also in line with findings in retrospective studies on Ki67 [11, 26, 27] , and on genetic profiling, where the main common denominator in different profiles is proliferation genes [2]. Ki67 [1] and the most studied genetic profiles [1, 3] are therefore now to some extent recommended for use in addition to conventional prognostic factors, even though there are no prospective trials yet published to support their use. There are numerous studies supporting the use of SPF, and even prospective studies [7, 8] , but its use has been limited by the need of fresh frozen tissue [11] . However, the 70-gene recurrence score also requires fresh frozen tumour tissue. There have also been reports of problems with reproducibility for SPF, but studies have shown that by use of guidelines [17, 28, 29] , reproducibility can be significantly improved. This is also proved by the present study, as analyses were carried out at four different laboratories in Sweden, and still the prognostic value was retained. The present prospective study therefore further supports the use of SPF. There is also a known strong correlation between SPF and other proliferation factors, such as Ki67 [26] . In a previous study, we demonstrated that the prognostic impact of Ki67 was restricted to ER-positive patients, whereas no prognostic effect was found in ER-negative patients [30] . We therefore also carried out exploratory analyses based on ER-status in the present study, and similar results were found. There was a very strong prognostic added value for BCSS of SPF in ER-positive patients, where only 2 of 259 ER-positive patients (0.8%) with low SPF died of breast cancer the first 5 years, compared with 11 of 93 ER-positive patients (12%) with high SPF, corresponding to a HR of 16. No significant prognostic effect was seen in ERnegative patients, and the differential prognostic effect of SPF in ER-positive and ER-negative patients corresponded to a significant interaction term (P = 0.03). This study therefore also gives further support to the added prognostic value of proliferation in general in node-negative breast cancer patients, and as previous studies have shown [30, 31] , and this study suggests, perhaps specifically to distinguish between the 'luminal A-' and 'luminal B-like'-subtypes [1]. The prognostic value of PR, especially in relation to ER, has been under debate [32] . Some studies have shown it to be a prognostic marker superior to ER [33, 34] , and others that it might be a predictor of response to endocrine therapy in ER-positive disease [35] , although there was no support for this finding in the latest Oxford overview [32] . In the present study, in univariate analysis, we could not find a difference in the prognostic strength between PR and ER, and when PR was replaced with ER in the index, the prognostic strength of 5-years BCSS was retained.
In summary, this prospective validation study on nodenegative breast cancer patients confirms that an index consisting of a proliferation factor, PR-status, and tumour size identifies a third of the patients as high risk, with an increased risk of death in breast cancer even after 15 years of follow-up. It also identifies a large group of patients, the 37% with no risk factors, with almost 100% 5-year BCSS. By use of conventional available prognostic factors only, a majority of lymph-node negative patients will today be over-treated, at the same time as a smaller fraction of patients will receive insufficient treatment [1, 36] . This prognostic index may therefore be useful in decisions on risk and adjuvant medical treatment.
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